anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: We investigate the role of osteopontin (OPN) in participants with Pre-symptomatic Alzheimer's disease (AD), mild cognitive impairment (MCI), and in AD brains.
METHODS: Cerebrospinal fluid (CSF) OPN, AD, and synaptic biomarker levels were measured in 109 cognitively unimpaired (CU), parental-history positive Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) participants, and in 167 CU and 399 participants with MCI from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. OPN levels were examined as a function of amyloid beta (Aβ) and tau positivity. Survival analyses investigated the link between OPN and rate of conversion to AD.
RESULTS: In PREVENT-AD, CSF OPN was positively correlated with synaptic biomarkers. In PREVENT-AD and ADNI, OPN was elevated in CSF Aβ42/40(+)/total tau(+) and CSF Aβ42/40(+)/phosphorylated tau181(+) individuals. In ADNI, OPN was increased in Aβ(+) positron emission tomography (PET) and tau(+) PET individuals, and associated with an accelerated rate of conversion to AD. OPN was elevated in autopsy-confirmed AD brains.
DISCUSSION: Strong associations between CSF OPN and key markers of AD pathophysiology suggest a significant role for OPN in tau neurobiology, particularly in the early stages of the disease.
HIGHLIGHTS: In the Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease cohort, we discovered that cerebrospinal fluid (CSF) osteopontin (OPN) levels can indicate early synaptic dysfunction, tau deposition, and neuronal loss in cognitively unimpaired elderly with a parental history. CSF OPN is elevated in amyloid beta(+) positron emission tomography (PET) and tau(+) PET individuals. Elevated CSF OPN is associated with an accelerated rate of conversion to Alzheimer's disease (AD). Elevated CSF OPN is associated with an accelerated rate of cognitive decline on the Alzheimer's Disease Assessment Scale-Cognitive subscale 13, Montreal Cognitive Assessment, Mini-Mental State Examination, and Clinical Dementia Rating Scale Sum of Boxes. OPN mRNA and protein levels are significantly upregulated in the frontal cortex of autopsy-confirmed AD brains.
The integration of ortholinguistic and paralinguistic functions in language, particularly of the emotional prosody, is necessary to interact adaptively with others. People in the schizophrenic spectrum have social difficulties. Is emotional prosody comprehension altered in these people? According to Edwards et al. (2002), there is methodological issues concerning the tasks used to answer this question. Investigators built an emotional judgment task more adapted to study the perception of emotional prosody in the schizophrenic spectrum than the classical paradigm designed to evaluate participants with cerebral injury. The investigators have elaborated a material that consists of 140 short sentences (7±2 words) with a simple syntactic structure. The verbal content expressed positive, neutral or negative emotions. These sentences were announced by four professional actors (two female) with an emotional prosody content congruent or inconsistent with the verbal content. Participants will have to evaluate the emotional intensity of the recordings on a five points Likert scale, from strongly negative to strongly positive. Psychotic experiences of all participants will be evaluated too.
Low-flow oxygen supplementation if respiratory danger signs are present or if their oxygen saturation is \<90%. Respiratory danger signs include any of the following: grunting, severe chest indrawing, very fast breathing (\>70 breaths/minute if 1-11 months; \>60 breaths/minute if 12-59 months), nasal flaring, stridor in a calm child, or apnea. Low-flow oxygen given by an oxygen concentrator with a nasal cannula. Low-flow is 0.5 liters per minute (LPM) for patients 1-2 months, and 1-2 LPM for patients 2-59 months. For 2-59 month olds oxygen can be increased to a maximum of 2 LPM to maintain a 90% saturation or treat respiratory danger signs.
Pharmaceutical compsn. for topical application contains an aq. soln. of a predetermined quantity of diosmin (I) in a strong base, one or more fatty acids of 10 - 14C atoms, a hydrating agent, a neutralisation agent, a gelling agent to give the product the desired texture, and opt. stabilisers and other adjuvants such as preservatives, colours, and perfumes. USE/ADVANTAGE - (I) is a known vascular-protecting veinotrope and veinotonic. It increases blood vessel resistance, decreases permeability, and vasoconstriction. Transdermal administration is difficult because of its poor solubility and relatively large size. The new compositions enable it to be administered without difficulty.
In the past decade, numerous tyrosine kinase inhibitors (TKIs) have been introduced in the treatment of chronic myeloid leukemia. Given the significant interpatient variability in TKIs pharmacokinetics, potential drug-drug interactions (DDIs) can greatly impact patient therapy. This review aims to discuss the pharmacokinetic characteristics of TKIs, specifically focusing on their absorption, distribution, metabolism, and excretion profiles. Additionally, it provides a comprehensive overview of the utilization of TKIs in special populations such as the elderly, children, and patients with liver or kidney dysfunction. We also highlight known or suspected DDIs between TKIs and other drugs, highlighting various clinically relevant interactions. Moreover, specific recommendations are provided to guide haemato-oncologists, oncologists, and clinical pharmacists in managing DDIs during TKI treatment in daily clinical practice.
This is a Phase Ib open-label, single-arm, single-dose study that will be conducted in up to 12 ROSAH syndrome patients. The study will investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DF-003 (study drug). DF-003 will be administered orally (PO), once daily (QD) for 28 days (4 weeks). Patients will be followed up for 8 weeks after administration of the last dose of study drug.

A total of 8 patients will be evaluated in one cohort. The cohort will have a minimum of 6 patients. Additional patients (maximum of 12 patients) may be enrolled in the event of insufficient data after a review of safety data by the Study Safety Committee. Patients will receive loading doses of 140 mg DF-003 on Days 1, 2, and 3, followed by a maintenance dose of 45 mg DF-003 starting on Day 4 through Day 28. Individual dose modification is not allowed in this study.
Inflamm-aging refers to the chronic low-grade inflammation that occurs with aging and cellular senescence, and it is linked to various diseases. Understanding the markers involved in inflammation and aging, as well as their interaction with environmental factors and bodily control mechanisms, can provide crucial tools for assessing the resilience (i.e. the ability to adapt and improve) of the human body, particularly in the presence of chronic degenerative conditions or vulnerable life stages, that place the individual and the community to which he belongs in a state of potential fragility. HEBE focuses on physical exercise, along with nutritional and lifestyle recommendations, to reduce systemic inflammation and promote healthy aging. HEBE encompasses multiple research lines (LR). In the ongoing LR1 ("proof of concept"), healthy lifestyle recommendations were provided to University of Milan employees, and changes in quality of life and well-being were assessed using a specialized questionnaire. The first 100 eligible subjects, who expressed their willingness to participate, underwent a personalized physical exercise protocol based on clinical and objective assessments. Biomedical samples were collected at baseline (T0) and follow-up (T1) to establish a shared biobank and identify non-invasive biomarkers that monitor the impact of physical exercise on individual characteristics such as cardiovascular and metabolic health. Subsequently (LR2-LR10), the proof of concept findings will be expanded to include various conditions of vulnerability such as obesity, cancer, endocrine disorders, cardiovascular diseases, infertility, functional syndromes, respiratory disorders, neurodegenerative diseases, and autoimmune conditions. The research lines will leverage the expertise of the 94 participating investigators to form a collaborative network that maximizes the potential for investigation and knowledge exchange. This approach fosters a culture of health promotion and disease prevention. ClinicalTrials.gov Identifier: NCT05815732.
The molecular and genetic mechanisms underlying left atrial (LA) enlargement and atrial fibrosis following right ventricular (RV) dependent pacing remain unclear. Our objective was to investigate genetic expressions in the LA of pigs subjected to RV pacing for atrioventricular block (AVB), as well as to identify the differential gene expressions affected by biventricular (BiV) pacing. We established an AVB pig model and divided the subjects into three groups: a sham control group, an RV pacing group, and a BiV pacing group. Differential expression genes (DEGs) analyses conducted through next-generation sequencing (NGS) and enrichment analyses were employed to identify genes with altered expression in the LA myocardium. The RV pacing group showed a significant increase in extracellular fibrosis in the LA myocardium compared to the control group. NGS analysis revealed suppressed expression of the sirtuin signaling pathway in the RV pacing group. Among the DEGs within this pathway, GADD45G was found to be downregulated in the RV pacing group and upregulated in the BiV pacing group. Remarkably, the BiV pacing group exhibited elevated levels of GADD45G protein. In our study, we observed significant downregulation of SIRT1 and GADD45G genes, which are associated with the sirtuin signaling pathway, in the LA myocardium of the RV pacing group when compared to the control group. Moreover, these genes, which were downregulated in the RV pacing group, displayed a noteworthy upregulation in the BiV pacing group when compared to the RV pacing group.
PURPOSE:To produce the titled cosmetic having improved collapsibility of granule, compatibility with water and rough feeling on the skin, by compounding a surfactant to a granular cosmetic containing an oil-soluble drug and a water- soluble powder slightly soluble in alcohol. CONSTITUTION:A granular cosmetic having various advantages such as (i) easily collapsible granule, (ii) high compatibility with water and quick dispersion in water, (iii) free from rough feeling when applied to the skin, etc., is produced by compounding (A) a water-soluble powder slightly soluble in alcohol (e.g. a polyhydric alcohol such as D-mannitol, glucose, etc.), (B) an oil-soluble drug such as vitamin, antipruritic, keratolytic agent, sebum-secretion suppressing agent, trichogenous agent, etc.) and (C) a surfactant as essential components. The amounts of the components A and B are preferably 50-99.0wt% and 0.1-45wt% based on the whole granular cosmetic, respectively and the amount of the component C is 1/40-1/10pts. per 1pt. of the component B.
INTRODUCTION: The development of oral anticancer agents (OAA) has profoundly changed cancer care, leading patients to manage their chemotherapy treatment on an outpatient basis. The prevention of iatrogenic effects of OAA remains a major concern, especially since their side effects are not less serious than those of intravenous chemotherapy. The ONCORAL programme was set up to secure the management of OAA in cancer patients followed at the Lyon University Hospital. This multidisciplinary programme involves hospital pharmacists, nurses, oncologists, and haematologists, as well as community health professionals. Given the economic stakes that this programme entails for the health system, a medico-economic study was designed.
METHODS AND ANALYSIS: This is a prospective controlled study, with individual open-label randomisation. A total of 216 outpatients treated with OAA and at risk of developing a drug-related iatrogenic event, will be randomised (2:1) to undergo follow-up in the ONCORAL programme or usual care. The primary outcome will be the estimation of the incremental cost-effectiveness ratio (difference in total costs per quality adjusted life years gained) at 12 months between the two groups. The secondary outcomes will be evaluation of OAA management consequences (relative-dose intensity, adherence, adverse drug events, drug-drug interactions, and proven medication errors), evaluation of overall survival and cancer-related quality of life, and patient-reported outcomes in relation to the treatment. A budget impact analysis will be implemented. Patient and health professional satisfaction regarding the ONCORAL programme will be measured.
ETHICS AND DISSEMINATION: Approval to conduct this study was obtained from an Ethics Committee (Comité de Protection des Personnes Ile-de-France VI) in October 2019, and from the French data protection agency (Commission Nationale de l'Informatique et des Libertés), according to the French Law. Trial results will be disseminated at clinical conferences and published in peer-reviewed journals.
TRIAL REGISTRATION: NCT03660670.
Pregnancy Category B 

No studies with SITAVIG have been performed in pregnant women. Systemic exposure of acyclovir following buccal administration of SITAVIG is minimal. SITAVIG should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. There are no adequate and well-controlled studies of systemic acyclovir in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy between 1984 and 1999 followed 749 pregnancies in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximated that found in the general population. However, the size of the registry was insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses.

Animal Data

Animal reproduction studies have not been conducted with SITAVIG. Acyclovir was not teratogenic in the mouse, rabbit or rat at exposures greatly in excess of human exposure.
The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale. A gel pad with a temperature of -10 ° C and a homogeneous distribution when cooled will be placed so that the patient is in full contact with the silicone drain.Since the skin temperature must fall below 13.6 ° C for cold application to have a local analgesic effect, the application will be terminated when the patient's skin temperature is 13.6 ° C by measuring every one minute during the cold application and the physician will be informed that the patient is ready.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale15 minutes after the removal of the silicone drain.
The demonstrated benefits of increased protein intake on sarcopenia and many physiological functions is becoming increasingly evident. For this reason, there is growing importance to ensuring that Americans consume the recommended amount of protein, calculated to be 17-21% of caloric intake. As it relates to the prevention of sarcopenia, adequate protein consumption inherently assumes that sufficient protein is ingested to stimulate protein anabolism. Specifically, adequate essential amino acid precursors, and anabolic triggers such as leucine, must be present for protein anabolism to occur. Population data from the NHANES study suggests that American protein intake pattern is skewed towards the evening meal. The NHANES data also suggests that the average protein consumption of both men and women over the age of 50 yrs is approximately 1.1 g/kg/d. Thus, the prevalent consumption pattern ensures that many individuals consume adequate protein, or amino acid precursors sufficient to stimulate protein synthesis, only with the larger, or dinner meal. The investigators have demonstrated that frequent stimulation of protein synthesis with amino acids preserves strength and function. Others have demonstrated that adequate protein intake stimulates muscle protein synthesis and increases lean mass. Given these data, The investigators studied the effects of two different protein intake patterns on metabolic and functional outcomes in older individuals after 8 wks of dietary control. The mean protein intake for this group of 1.1 g/kg/d was consumed in two distinct meal patterns. Participants consumed high quality protein in the ratio of 15/20/65% of total protein intake for breakfast/lunch/dinner, respectively (Uneven protein intake pattern), or protein consumption was distributed equally among each meal (33% of total protein)(Even protein intake pattern). The investigators determined the longitudinal effects of this consumption pattern on the metabolic outcomes of whole-body net protein synthesis and muscle protein synthesis in older participants.
Microvascular dysfunction remains a major contributor to the development of skin complications. The inventors assessed the impact of the local inhibition of soluble epoxide hydrolase (sEH), which metabolizes vasodilator and anti-inflammatory epoxyeicosanoids, on the diabetic skin microvascular dysfunction. The inventors have therefore developed some formulations of sEH inhibitors (GSK2256294 and  t -AUCB) for topical administration. In particular, they show that an aqueous gel containing 400 mg/L  t -AUCB dissolved in 50% dimethy lsulfo xide (DMSO) allowed a stable and continuous diffusion of  t -AUCB from 2 hours after application on skin pig ears to over a period of 24h. Compared to a control gel, the gel with  t -AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients.
Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-Hepatitis B therapy including HEPSERA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-Hepatitis B therapy. If appropriate, resumption of anti-Hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)].

In patients at risk of or having underlying renal dysfunction, chronic administration of HEPSERA may result in nephrotoxicity. These patients should be monitored closely for renal function and may require dose adjustment [see Warnings and Precautions (5.2) and Dosage and Administration (2.2)].

HIV resistance may emerge in chronic hepatitis B patients with unrecognized or untreated Human Immunodeficiency Virus (HIV) infection treated with anti-hepatitis B therapies, such as therapy with HEPSERA, that may have activity against HIV [see Warnings and Precautions (5.3)].

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [see Warnings and Precautions (5.4)].
1. A gel form of a live vaccine for administration of live organisms to poultry hatchlings, the gel form comprising approximately 1 to 2.5 percent of a temperature setting gelling agent having suspended therein sufficient levels of live organisms to provide for immunization of a poultry hatchling flock. 2. The gel form of a live vaccine according to claim 1 wherein said gel form is prepared in the form of separate portions, the weight of which is sufficient for administering immunized dose of live organisms to a poultry flock. 3. The gel form of a live vaccine according to claim 1 wherein the gelling agent is present in concentration enabling to mix live organisms and the gelling agent to prepare a substantially homogenous suspension of live organisms prior to cooling the gelling agent to produce a gelled live vaccine stable in form. 4. The gel form of a live vaccine according to claim 1 wherein the live organisms are present in concentration which provides an optimum immunization level of live organisms in the gelled live vaccine allowing the poultry hatching flock to feed from the gelled vaccine suspension. 5. The gel form of a live vaccine according to claim 1 wherein the live organisms are oocysts of Eimeria sp. 6. The gel form of a live vaccine according to claim 5 wherein the oocysts are selected from one or more of Eimeria tenella, Eimeria necatrix, Eimeria acervulina, Eimeria maxima, Eimeria brunetti, Eimeria praecox and Eimeria mitis. 7. The gel form of a live vaccine according to claim 5 wherein the vaccine contains between about 200 and 300 oocysts per ml. 8. The gel form of a live vaccine according to claim 1 wherein the gelling agent is an alginate or a kappa carrageenan. 9. The gel form of a live vaccine according to claim 1 wherein the gelling agent is a kappa carrageenan. 10. The gel form of a live vaccine according to claim 9 wherein the vaccine contains from about 1.0 percent to about 2.0 percent of an gelling agent. 11. A method for immunizing a poultry flock, the method comprising: i) preparing a suspension of the viable organisms; ii) dissolving an edible polysaccharide temperature dependent gelling agent in an aqueous solution, said gelling agent is added in a concentration sufficient to produce a gelled live vaccine stable in form; iii) mixing the live organism suspension and the gelling agent solution; iv) allowing the mixture to cool and gel being stable in form to produce live immunogen organisms substantially homogeniuosly suspended in gel stable in form; and  v) feeding the poultry hatching flock a gel form. 12. The method according to claim 11 wherein the poultry hatching flock is immunized in an incubator. 13. The method according to claim 11 wherein the poultry hatching flock is subjected to substantially homogenous feeding by live immunogen organisms, since the live organisms are substantially suspended homogenously in the gel form.
1. A vaccine mixture against respiratory system pathologies in cattle, characterised in that it comprises at least three valencies of polynucleotide vaccines. Each of them comprises an integrating plasmoid, which covers a gene of one cattle pathogen valency, which expresses it in vivo in a host cell, while the valencies are selected from a group, consisting of cattle herpesvirus, syncythial virus of cattle respiratory system, muciositis virus and type 3 parainfluenza virus. For each valence, the plasmoids comprise one or several genes, selected from the group, consisting of gB and gD for the cattle herpes virus, F and G for syncythial virus of cattle respiratory system, E2, C + E1 + E2 and E1 + E2 for the mociositis virus, HN and F for type 3 parainfluenza virus. 8. Application of one or several plasmoids, as indicated in claims 1-7, to produce a vaccine for the vaccination of cattle, previously vaccinated with a vaccine selected from a group, which comprises: a full live vaccine, a full inactivated vaccine, a subunit vaccine, a recombined vaccine. the first vaccine has (an) antigen(s) coded by the plasmoid or (an) antigen(s) ensuring cross immunity. 9. A vaccination set, covering a vaccinating mixture defined in claim 1, and the first vaccine, selected from the group comprising: a full live vaccine, a full inactivated vaccine, a subunit vaccine, a recombined vaccine. The first vaccine has an antigen, coded by a polynucleotide vaccine or an antigen ensuring cross immunity. The set is designed for the administration of the first vaccine during first vaccination and of the vaccinating mixture during booster vaccination.